In this study, we address these knowledge gaps through our primary objective where we sought to characterise real‐world WL efficacy, quantify the impact of digital engagement on outcomes, and establish the safety profile of integrated digital‐pharmacological obesity management with dual GIP/GLP‐1RA and GLP‐1RA over 11 months of follow‐up in the ‘Voy’ DWLS. The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.